Adenoid Cystic Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: ADN011 MIFTS: 66	Adenoid Cystic Carcinoma Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Neuronal diseases, Oral diseases, Rare diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Adenoid Cystic Carcinoma

MalaCards integrated aliases for Adenoid Cystic Carcinoma:

Name: Adenoid Cystic Carcinoma ¹² ¹² ⁷⁷ ⁵⁴ ⁶ ¹⁵ ¹⁷ ⁷⁴

Salivary Gland Adenoid Cystic Carcinoma ¹² ⁵⁶ ¹⁵

Cylindroma ¹² ⁵⁴

Adenoid Cystic Carcinoma of Salivary Gland ⁷⁴

Carcinoma, Adenoid Cystic ⁴⁵

Eccrine Dermal Cylindroma ⁷⁴

Carcinoma Adenoid Cystic ⁵⁶

Adenoid Cystic Cancer ¹²

Adenocystic Carcinoma ⁵⁴

Carcinoma, Cribriform ⁷⁴

Cribriform Carcinoma ⁵⁴

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Oral diseases Neuronal diseases Skin diseases Endocrine diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:0080202 DOID:4866

MeSH ⁴⁵ D003528

NCIt ⁵¹ C2970

SNOMED-CT ⁶⁹ 11671000

EFO ¹⁷ EFO_0000231

UMLS ⁷⁴ C0010606 C0205643 C0279751 more

Sources

Summaries for Adenoid Cystic Carcinoma

NIH Rare Diseases : ⁵⁴ Adenoid cystic carcinoma (ACC) is a rare form of adenocarcinoma, a type of cancer that begins in glandular tissues. It most commonly arises in the major and minor salivary glands of the head and neck. It can also occur in the breast, uterus, or other locations in the body. Symptoms depend on the tumor's location. Salivary gland tumors may cause painless masses in the mouth or face. Tumors of the lacrimal gland may cause a bulging eye or changes in vision. Those affecting the windpipe or voice box may cause respiratory symptoms or changes in speech, respectively. Advanced tumors may cause pain and/or nerve paralysis, as ACC often spreads along the nerves. It may also spread through the bloodstream. It spreads to the lymph nodes in about 5% to 10% of cases. The cause of ACC is currently unknown. It typically does not run in families. Treatment depends on many factors and may include surgery, radiation, and/or chemotherapy. Unfortunately, ACC is typically an aggressive form of cancer that has a poor long-term outlook.

MalaCards based summary : Adenoid Cystic Carcinoma, also known as salivary gland adenoid cystic carcinoma, is related to prostate adenoid cystic carcinoma and lung adenoid cystic carcinoma, and has symptoms including pain An important gene associated with Adenoid Cystic Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Fentanyl and Histamine have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, breast and lung, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : ¹² A salivary gland carcinoma that is characterized by a distinctive pattern in which abnormal nests or cords of epithelial cells surround and/or infiltrate ducts or glandular structures within the affected organ. These structures are typically filled with a mucous-like material or contain abnormal fibrous membranes.

Wikipedia : ⁷⁷ Adenoid cystic carcinoma (sometimes referred to as adenocyst, malignant cylindroma, adenocystic,... more...

Sources

Related Diseases for Adenoid Cystic Carcinoma

Diseases related to Adenoid Cystic Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 372)

#	Related Disease	Score	Top Affiliating Genes
1	prostate adenoid cystic carcinoma	34.9	HRAS PIK3CA
2	lung adenoid cystic carcinoma	34.7	HRAS KIT KRAS NFIB PIK3CA
3	breast adenoid cystic carcinoma	34.6	ERBB2 KIT NFIB
4	prostate cancer	32.2	CCND1 CDH1 ERBB2 HRAS KRAS PIK3CA
5	pleomorphic adenoma	32.0	ERBB2 KRT14 TP53
6	polymorphous low-grade adenocarcinoma	31.8	CCND1 KIT MYB NFIB
7	adenocarcinoma	31.6	CCND1 CDH1 ERBB2 HRAS KIT KRAS
8	mucoepidermoid carcinoma	31.4	ERBB2 KRT14 KRT7
9	squamous cell carcinoma	31.3	CCND1 CDH1 ERBB2 HRAS NOTCH1 PIK3CA
10	small cell carcinoma	31.1	KIT KRT7 PTEN TP53
11	sarcoma	31.0	HRAS KIT KRAS PIK3CA TP53
12	gliosarcoma	30.9	IDH1 PTEN TP53
13	differentiated thyroid carcinoma	30.9	HRAS KRAS TP53
14	epithelial-myoepithelial carcinoma	30.8	FBXW7 HRAS KRT14 KRT7 TP53
15	basaloid squamous cell carcinoma	30.7	KRT14 KRT7 TP53
16	teratoma	30.7	KIT KRT7 TP53
17	thyroid cancer	30.7	CCND1 CDH1 HRAS KIT KRAS PIK3CA
18	papillary carcinoma	30.7	CDH1 ERBB2 KRT7
19	sarcoma, synovial	30.7	CDH1 KIT KRT7
20	papilloma	30.7	CCND1 KRT14 KRT7 PTEN TP53
21	gastric cancer	30.6	CCND1 CDH1 ERBB2 KRAS PIK3CA PTEN
22	malignant spiradenoma	30.6	KRT7 PIK3CA TP53
23	spindle cell carcinoma	30.6	CDH1 KRT14 KRT7
24	carcinosarcoma	30.6	ERBB2 HRAS KIT KRAS KRT7 PIK3CA
25	glioblastoma	30.6	CCND1 ERBB2 HRAS IDH1 PIK3CA PTEN
26	spiradenoma	30.6	CYLD KRT14 KRT7 TP53
27	nasopharyngeal carcinoma	30.6	CCND1 CDH1 HRAS PIK3CA STAT3 TP53
28	breast cancer	30.5	CCND1 CDH1 ERBB2 FBXW7 HRAS IDH1
29	squamous cell carcinoma, head and neck	30.5	CCND1 CDH1 ERBB2 HRAS PIK3CA PTEN
30	transitional cell carcinoma	30.5	CDH1 ERBB2 HRAS KRT7 PTEN TP53
31	renal cell carcinoma, papillary, 1	30.4	ERBB2 HRAS KIT KRT7 PIK3CA PTEN
32	necrotizing sialometaplasia	30.4	KIT KRT7 TP53
33	lung cancer susceptibility 3	30.3	CCND1 CDH1 ERBB2 HRAS IDH1 KRAS
34	brooke-spiegler syndrome	30.3	CYLD KRT14 KRT7
35	lung cancer	30.2	CCND1 CDH1 ERBB2 HRAS KIT KRAS
36	hepatocellular carcinoma	30.1	CCND1 CDH1 HRAS IDH1 KRAS KRT7
37	cervical adenoid cystic carcinoma	12.8
38	maxillary sinus adenoid cystic carcinoma	12.6
39	lacrimal gland adenoid cystic carcinoma	12.6
40	trachea adenoid cystic carcinoma	12.6
41	laryngeal adenoid cystic carcinoma	12.6
42	esophageal adenoid cystic carcinoma	12.5
43	parotid gland adenoid cystic carcinoma	12.5
44	bartholin's gland adenoid cystic carcinoma	12.5
45	cribriform carcinoma	12.5
46	ethmoid sinus adenoid cystic carcinoma	12.4
47	cylindromatosis, familial	12.4
48	adenoid cystic carcinoma of the corpus uteri	12.4
49	sublingual gland adenoid cystic carcinoma	12.3
50	lymph node adenoid cystic carcinoma	12.3

Graphical network of the top 20 diseases related to Adenoid Cystic Carcinoma:

Sources

Symptoms & Phenotypes for Adenoid Cystic Carcinoma

UMLS symptoms related to Adenoid Cystic Carcinoma:

pain

GenomeRNAi Phenotypes related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

²⁷ (show top 50) (show all 63)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-2	10.6	KRAS HRAS PIK3CA
2	Decreased viability	GR00106-A-0	10.6	KRAS
3	Decreased viability	GR00221-A-1	10.6	CDH1 CYLD KIT KRAS HRAS PIK3CA
4	Decreased viability	GR00221-A-2	10.6	CYLD KRAS HRAS PIK3CA
5	Decreased viability	GR00221-A-3	10.6	HRAS
6	Decreased viability	GR00221-A-4	10.6	PIK3CA
7	Decreased viability	GR00301-A	10.6	CDH1 CYLD KIT KRAS
8	Decreased viability	GR00381-A-1	10.6	KRAS
9	Decreased viability	GR00402-S-2	10.6	CDH1 CYLD KIT KRAS HRAS PIK3CA
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-100	10.38	MYB
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-105	10.38	NFIB
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-11	10.38	KRAS
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-115	10.38	NFIB
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-116	10.38	PIK3CA
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-120	10.38	KRAS MYB
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-121	10.38	FBXW7 MYB
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-122	10.38	FBXW7 MYB
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-126	10.38	CCND1
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-147	10.38	MYB
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-152	10.38	CCND1 FBXW7
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-157	10.38	FBXW7 PIK3CA
22	Increased shRNA abundance (Z-score > 2)	GR00366-A-16	10.38	CCND1 PIK3CA
23	Increased shRNA abundance (Z-score > 2)	GR00366-A-161	10.38	MYB
24	Increased shRNA abundance (Z-score > 2)	GR00366-A-163	10.38	CCND1
25	Increased shRNA abundance (Z-score > 2)	GR00366-A-164	10.38	MYB
26	Increased shRNA abundance (Z-score > 2)	GR00366-A-166	10.38	PIK3CA
27	Increased shRNA abundance (Z-score > 2)	GR00366-A-168	10.38	KRAS
28	Increased shRNA abundance (Z-score > 2)	GR00366-A-169	10.38	MYB
29	Increased shRNA abundance (Z-score > 2)	GR00366-A-177	10.38	CCND1 FBXW7 KRAS MYB NFIB PIK3CA
30	Increased shRNA abundance (Z-score > 2)	GR00366-A-183	10.38	FBXW7
31	Increased shRNA abundance (Z-score > 2)	GR00366-A-190	10.38	PIK3CA
32	Increased shRNA abundance (Z-score > 2)	GR00366-A-196	10.38	KRAS
33	Increased shRNA abundance (Z-score > 2)	GR00366-A-199	10.38	CCND1
34	Increased shRNA abundance (Z-score > 2)	GR00366-A-21	10.38	CCND1
35	Increased shRNA abundance (Z-score > 2)	GR00366-A-210	10.38	CCND1
36	Increased shRNA abundance (Z-score > 2)	GR00366-A-23	10.38	KRAS
37	Increased shRNA abundance (Z-score > 2)	GR00366-A-25	10.38	CCND1 NFIB
38	Increased shRNA abundance (Z-score > 2)	GR00366-A-35	10.38	NFIB
39	Increased shRNA abundance (Z-score > 2)	GR00366-A-36	10.38	CCND1
40	Increased shRNA abundance (Z-score > 2)	GR00366-A-42	10.38	PIK3CA
41	Increased shRNA abundance (Z-score > 2)	GR00366-A-43	10.38	FBXW7
42	Increased shRNA abundance (Z-score > 2)	GR00366-A-49	10.38	KRAS PIK3CA
43	Increased shRNA abundance (Z-score > 2)	GR00366-A-50	10.38	KRAS
44	Increased shRNA abundance (Z-score > 2)	GR00366-A-52	10.38	FBXW7
45	Increased shRNA abundance (Z-score > 2)	GR00366-A-63	10.38	KRAS
46	Increased shRNA abundance (Z-score > 2)	GR00366-A-65	10.38	MYB
47	Increased shRNA abundance (Z-score > 2)	GR00366-A-73	10.38	MYB
48	Increased shRNA abundance (Z-score > 2)	GR00366-A-83	10.38	MYB
49	Increased shRNA abundance (Z-score > 2)	GR00366-A-93	10.38	KRAS
50	Decreased shRNA abundance (Z-score < -2)	GR00366-A-139	10.2	NOTCH1

MGI Mouse Phenotypes related to Adenoid Cystic Carcinoma:

⁴⁷ (show all 24)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.51	CCND1 CDH1 CYLD ERBB2 FBXW7 JAK3
2	endocrine/exocrine gland	MP:0005379	10.51	CCND1 CDH1 CYLD ERBB2 FBXW7 HRAS
3	growth/size/body region	MP:0005378	10.51	CCND1 CDH1 CYLD ERBB2 FBXW7 HRAS
4	homeostasis/metabolism	MP:0005376	10.49	CCND1 CDH1 CYLD ERBB2 FBXW7 HRAS
5	digestive/alimentary	MP:0005381	10.47	CCND1 CDH1 CYLD ERBB2 FBXW7 HRAS
6	mortality/aging	MP:0010768	10.46	CCND1 CDH1 CYLD ERBB2 FBXW7 HRAS
7	cardiovascular system	MP:0005385	10.43	CCND1 CDH1 ERBB2 FBXW7 HRAS KIT
8	immune system	MP:0005387	10.42	CCND1 CDH1 CYLD FBXW7 IDH1 JAK3
9	integument	MP:0010771	10.41	CCND1 CDH1 CYLD ERBB2 FBXW7 HRAS
10	hematopoietic system	MP:0005397	10.38	CCND1 CYLD FBXW7 IDH1 JAK3 KIT
11	craniofacial	MP:0005382	10.35	CCND1 ERBB2 FBXW7 HRAS KIT KRAS
12	embryo	MP:0005380	10.33	CDH1 ERBB2 FBXW7 KIT KRAS MYB
13	neoplasm	MP:0002006	10.32	CCND1 CDH1 CYLD ERBB2 FBXW7 HRAS
14	nervous system	MP:0003631	10.23	CCND1 ERBB2 FBXW7 HRAS KIT KRAS
15	normal	MP:0002873	10.22	CCND1 CDH1 CYLD ERBB2 FBXW7 HRAS
16	liver/biliary system	MP:0005370	10.13	FBXW7 KIT KRAS MYB NOTCH1 PTEN
17	muscle	MP:0005369	10.1	ERBB2 KIT KRAS NOTCH1 PIK3CA PTEN
18	respiratory system	MP:0005388	10	CCND1 CYLD ERBB2 FBXW7 HRAS IDH1
19	no phenotypic analysis	MP:0003012	9.98	CDH1 HRAS KIT KRAS MYB PIK3CA
20	reproductive system	MP:0005389	9.96	CCND1 CDH1 ERBB2 KIT KRAS KRT14
21	renal/urinary system	MP:0005367	9.92	HRAS KIT KRAS KRT7 NOTCH1 PTEN
22	pigmentation	MP:0001186	9.85	KIT KRAS KRT14 NOTCH1 PTEN TP53
23	skeleton	MP:0005390	9.7	CCND1 ERBB2 HRAS IDH1 KIT KRAS
24	vision/eye	MP:0005391	9.36	CCND1 FBXW7 KIT KRAS KRT14 NFIB

Sources

Drugs & Therapeutics for Adenoid Cystic Carcinoma

Drugs for Adenoid Cystic Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 179)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 3

437-38-7

3345

Histamine

Approved, Investigational

Phase 3

51-45-6

774

Doxepin

Approved, Investigational

Phase 3

1668-19-5

667468 667477

Diphenhydramine

Approved, Investigational

Phase 3

147-24-0, 58-73-1

3100

Promethazine

Approved, Investigational

Phase 3

60-87-7

4927

Fluconazole

Approved, Investigational

Phase 2, Phase 3

86386-73-4

3365

Miconazole

Approved, Investigational, Vet_approved

Phase 2, Phase 3,Phase 1

22916-47-8

4189

Cevimeline

Approved

Phase 3

107233-08-9

25137844 83898

Megestrol acetate

Approved, Investigational, Vet_approved

Phase 3

595-33-5

11683

Docetaxel

Approved, Investigational

Phase 3,Phase 1,Phase 2

114977-28-5

148124

Pancreatic Polypeptide

Investigational

Phase 3,Phase 1

59763-91-6

Porfiromycin

Investigational

Phase 3

801-52-5

Liver Extracts

Phase 3,Phase 2,Phase 1,Early Phase 1

Cola

Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Cytochrome P-450 Enzyme Inhibitors

Phase 2, Phase 3

Anti-Infective Agents

Phase 2, Phase 3,Phase 1

Narcotics

Phase 3

Adjuvants, Anesthesia

Phase 3

Analgesics

Phase 3

Anesthetics, Intravenous

Phase 3

Anesthetics, General

Phase 3

Anesthetics

Phase 3

Analgesics, Opioid

Phase 3

Central Nervous System Depressants

Phase 3

Peripheral Nervous System Agents

Phase 3,Not Applicable

Alkylating Agents

Phase 3,Phase 2,Phase 1,Early Phase 1

Nucleic Acid Synthesis Inhibitors

Phase 3,Phase 1,Phase 2

Antibiotics, Antitubercular

Phase 3,Phase 2,Phase 1

Anti-Bacterial Agents

Phase 3,Phase 2,Phase 1

Mitomycins

Phase 3

Histamine Antagonists

Phase 3

Psychotropic Drugs

Phase 3

Neurotransmitter Agents

Phase 3,Not Applicable

Antidepressive Agents, Tricyclic

Phase 3

Antidepressive Agents

Phase 3

Histamine Phosphate

Phase 3

51-74-1

65513

Hypnotics and Sedatives

Phase 3

Hormones

Phase 2, Phase 3,Phase 1

Steroid Synthesis Inhibitors

Phase 2, Phase 3

Hormone Antagonists

Phase 2, Phase 3

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 2, Phase 3

Cytochrome P-450 CYP2C9 Inhibitors

Phase 2, Phase 3

Antifungal Agents

Phase 2, Phase 3,Phase 1

Cytochrome P-450 CYP2C19 Inhibitors

Phase 2, Phase 3

Muscarinic Agonists

Phase 3

Autonomic Agents

Phase 3,Not Applicable

Cholinergic Agents

Phase 3,Not Applicable

Contraceptives, Oral

Phase 3

Appetite Stimulants

Phase 3

Central Nervous System Stimulants

Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 121)

#	Name	Status	NCT ID	Phase	Drugs
1	Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain	Completed	NCT00538850	Phase 3	Fentanyl sublingual spray;Placebo
2	Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer	Completed	NCT00002507	Phase 3	mitomycin C;porfiromycin
3	Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract	Completed	NCT00765440	Phase 3
4	Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy	Completed	NCT01156142	Phase 3	doxepin hydrochloride
5	Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer	Completed	NCT00090337	Phase 3
6	Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer	Completed	NCT00002533	Phase 2, Phase 3	fluconazole
7	Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer	Completed	NCT00017511	Phase 3	cevimeline hydrochloride
8	Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer	Completed	NCT00006799	Phase 3	megestrol acetate
9	Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery	Withdrawn	NCT00041171	Phase 3	Hypericum perforatum;docetaxel
10	Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck	Unknown status	NCT00180921	Phase 2	Imatinib
11	Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy	Unknown status	NCT01192087	Phase 1, Phase 2	Cetuximab
12	External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases	Unknown status	NCT00637637	Phase 2	indinavir sulfate;ritonavir
13	Study of RAD001 in Adenoid Cystic Carcinoma	Completed	NCT01152840	Phase 2	RAD001
14	A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands	Completed	NCT00886132	Phase 2	Sunitinib
15	Dovitinib in Adenoid Cystic Carcinoma	Completed	NCT01417143	Phase 2	TKI258 (Dovitinib):
16	Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck	Completed	NCT00581360	Phase 2	doxorubicin and bortezomib
17	Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma	Completed	NCT01558661	Phase 2	AG-013736 (AXITINIB)
18	Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma	Completed	NCT01524692	Phase 2	Dovitinib (TKI258)
19	A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands	Completed	NCT01678105	Phase 2	Dovitinib
20	Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma	Completed	NCT01175980	Phase 2	Vorinostat
21	Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck	Completed	NCT00077428	Phase 2	bortezomib;doxorubicin hydrochloride
22	Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers	Completed	NCT00095563	Phase 2	lapatinib ditosylate
23	Gemcitabine in Treating Patients With Recurrent or Metastatic Adenoid Cystic Cancer of the Head and Neck	Completed	NCT00017498	Phase 2	gemcitabine hydrochloride
24	Nelfinavir in Recurrent Adenoid Cystic Cancer of the Head and Neck	Completed	NCT01065844	Phase 2	Nelfinavir
25	Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors	Completed	NCT00859937	Phase 2	Dasatinib
26	Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma	Completed	NCT01604772	Phase 2	Akt Inhibitor MK2206
27	Imatinib Mesylate in Treating Patients With Salivary Gland Cancer	Completed	NCT00045669	Phase 2	imatinib mesylate
28	Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy	Completed	NCT02123511	Phase 2	acetylcysteine
29	Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer	Completed	NCT00492089	Phase 2	bevacizumab;placebo
30	Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer	Completed	NCT00101348	Phase 1, Phase 2	erlotinib hydrochloride
31	Chemotherapy in Treating Patients With Solid Tumors	Completed	NCT00003103	Phase 1, Phase 2	docetaxel
32	High-dose ICE With Amifostine	Completed	NCT00003657	Phase 2	Amifostine;Carboplatin;Etoposide;Ifosfamide
33	Docetaxel in Treating Patients With Solid Tumors	Completed	NCT00003565	Phase 2	docetaxel
34	Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer	Completed	NCT00448552	Phase 2	capecitabine;oxaliplatin
35	Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth Cancer	Completed	NCT00004901	Phase 1, Phase 2	ethynyluracil;fluorouracil;hydroxyurea
36	Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor	Completed	NCT00021047	Phase 1, Phase 2	capecitabine;carboplatin;epirubicin hydrochloride
37	Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors	Completed	NCT00019331	Phase 2	DetoxPC
38	Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases	Completed	NCT00154388	Phase 2	Imatinib mesylate
39	Cisplatin or Carboplatin Combined With Gemcitabine in Treating Patients With Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor	Completed	NCT00079079	Phase 2	carboplatin;cisplatin;gemcitabine hydrochloride
40	Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer	Completed	NCT00004163	Phase 2	Trastuzumab
41	Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery	Completed	NCT00003744	Phase 2	gemcitabine
42	Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer	Completed	NCT00509665	Phase 2	doxorubicin hydrochloride;gemcitabine hydrochloride
43	Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer	Completed	NCT00021333	Phase 2	cisplatin;paclitaxel
44	Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma	Recruiting	NCT02942693	Phase 2	Apatinib
45	Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety	Recruiting	NCT02883374	Phase 2	Chidamide
46	Chidamide Combined With Cisplatin in Head and Neck Adenoid Cystic Carcinoma (HNACC)	Recruiting	NCT03639168	Phase 2	Chidamide combined with cisplatin
47	A Study Of AL101 In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations	Recruiting	NCT03691207	Phase 2	AL101
48	Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer	Recruiting	NCT03146650	Phase 2
49	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors	Recruiting	NCT02834013	Phase 2
50	Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer	Recruiting	NCT03172624	Phase 2	Nivolumab;Ipilimumab

Search NIH Clinical Center for Adenoid Cystic Carcinoma

Cochrane evidence based reviews: carcinoma, adenoid cystic

Sources

Genetic Tests for Adenoid Cystic Carcinoma

Sources

Anatomical Context for Adenoid Cystic Carcinoma

MalaCards organs/tissues related to Adenoid Cystic Carcinoma:

⁴²

Salivary Gland, Breast, Lung, Trachea, Prostate, Brain, Cervix

Sources

Publications for Adenoid Cystic Carcinoma

Articles related to Adenoid Cystic Carcinoma:

(show top 50) (show all 2183)

#	Title	Authors	Year
1	Adenoid Cystic Carcinoma With Sialolithiasis of the Left Submandibular Gland: A Case Report and Literature Review. ( 30482073 )	Miyabe S...Nagao T	2019
2	PTEN downregulates WD repeat‑containing protein 66 in salivary adenoid cystic carcinoma. ( 30569117 )	Cao Y...Xiao J	2019
3	Clinicopathological and Molecular Characteristics of Mammary Adenoid Cystic Carcinoma With Adipocytic Differentiation With Emphasis on the Identification of a Novel BRAF Mutation. ( 30591482 )	Bae GE...Cho SY	2019
4	Adenoid cystic carcinoma of the vagina: A case report. ( 30608403 )	Zhang LZ...Yang F	2019
5	What are the multimode sonographic features of adenoid cystic carcinoma metastasized to the thyroid? ( 30614858 )	Zhao HN...Ma BY	2019
6	Impact of lymph node sampling on survival in cN0 major salivary gland adenoid cystic carcinoma. ( 30620437 )	Qian ZJ...Megwalu UC	2019
7	Successful management of recurrent adenoid cystic carcinoma in the deep infratemporal fossa by maxillo-orbito-zygomatic approach. ( 30626547 )	Hongo T...Masuda M	2019
8	Lack of Deletion of 1p36 in 8 Cases of Primary Adenoid Cystic Carcinoma of the Skin. ( 30640762 )	Kyrpychova L...Kazakov DV	2019
9	Adenoid cystic carcinoma of the sinonasal tract: a review of the national cancer database. ( 30645040 )	Trope M...Brant JA	2019
10	The Role of Elective Neck Dissection in Patients With Adenoid Cystic Carcinoma of the Head and Neck. ( 30667061 )	Xiao R...Deschler DG	2019
11	MIF promotes perineural invasion through EMT in salivary adenoid cystic carcinoma. ( 30667094 )	Zhang M...Tang YL	2019
12	Long-term Outcomes of Globe-Preserving Surgery with Proton Beam Radiation for Adenoid Cystic Carcinoma of the Lacrimal Gland. ( 30686477 )	Esmaeli B...Frank SJ	2019
13	Adenoid cystic carcinoma of the breast. ( 30697408 )	Thomas DN...Xiao P	2019
14	Computed tomographic features of adenoid cystic carcinoma in the palate. ( 30704527 )	Ju WT...Zhong LP	2019
15	Long-term Outcomes of Globe-Preserving Surgery With Proton Beam Radiation for Adenoid Cystic Carcinoma of Lacrimal Gland. ( 30709640 )	Wolkow N...Lee H	2019
16	Adenoid Cystic Carcinoma of Buccal Mucosa: Role of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Detection and Biopsy of Pulmonary Metastases and Assessment of Treatment Response. ( 30713389 )	Parihar AS...Bahl A	2019
17	The role of organ- and function-preserving radiotherapy in the treatment of adenoid cystic carcinoma of the larynx. ( 30723979 )	Akbaba S...Adeberg S	2019
18	Fibroblast growth factor receptor 1 (FGFR1) as a therapeutic target in adenoid cystic carcinoma of the lacrimal gland. ( 30728899 )	Doddapaneni R...Pelaez D	2019
19	Personalized Treatment for Lacrimal Sac Adenoid Cystic Carcinoma: Case Report and Literature Review. ( 30731273 )	Bowen RC...Lucarelli MJ	2019
20	Role of apoptotic, autophagic and senescence pathways in minor salivary gland adenoid cystic carcinoma. ( 30736793 )	Goulart-Filho JAV...de Ara?jo VC	2019
21	Pretreatment assessment of hematologic and inflammatory markers in adenoid cystic carcinoma: neutrophil/lymphocyte ratio is associated with multiple recurrences. ( 30745209 )	Brkic FF...Heiduschka G	2019
22	Autophagy-related gene expression regulated by HIF-1α in salivary adenoid cystic carcinoma. ( 30746817 )	Liu C...Zhang D	2019
23	The value of MYB as a prognostic marker for adenoid cystic carcinoma: A meta-analysis. ( 30759319 )	Liu X...Liang Y	2019
24	Adenoid cystic carcinoma with high-grade transformation forming spindle cell component of the submandibular gland. ( 30777403 )	Miyazaki M...Nabeshima K	2019
25	Treatment-induced changes of lymphocyte subsets in patients with adenoid cystic carcinoma of the head and neck. ( 30815724 )	Jeske SS...Doescher J	2019
26	Combined surgery and radiotherapy as curative treatment for tracheal adenoid cystic carcinoma: a case report. ( 30836992 )	Spinelli GP...Tomao S	2019
27	Analysis of clinicopathological characteristics, MYB rearrangement and prognostic factors in salivary adenoid cystic carcinoma. ( 30854068 )	Han J...Zhang C	2019
28	Sympathetic innervation contributes to perineural invasion of salivary adenoid cystic carcinoma via the β2-adrenergic receptor. ( 30863115 )	Ma C...Sun M	2019
29	MYB promotes the growth and metastasis of salivary adenoid cystic carcinoma. ( 30896785 )	Xu LH...Li SL	2019
30	Primary Adenoid Cystic Carcinoma of the Frontal Sinus: Case Description of a Previously Unreported Entity and Literature Review. ( 30922111 )	Tirelli G...Marcuzzo AV	2019
31	Results of a combination treatment with intensity modulated radiotherapy and active raster-scanning carbon ion boost for adenoid cystic carcinoma of the minor salivary glands of the nasopharynx. ( 30926061 )	Akbaba S...Adeberg S	2019
32	Clinically Integrated Molecular Diagnostics in Adenoid Cystic Carcinoma. ( 30926674 )	Thierauf J...Lennerz JK	2019
33	Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma. ( 30939095 )	Tchekmedyian V...Ho AL	2019
34	Hypoxia promotes vasculogenic mimicry formation by vascular endothelial growth factor A mediating epithelial-mesenchymal transition in salivary adenoid cystic carcinoma. ( 30945361 )	Wang HF...Liang XH	2019
35	Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma. ( 30953269 )	Even C...Massard C	2019
36	Fine-needle aspiration cytology of an adenoid cystic carcinoma of trachea: Common tumor in uncommon location. ( 30953393 )	Kaur G...Dey P	2019
37	Ultrasound guided generation of PDOX models of adenoid cystic carcinoma. ( 30954459 )	Seshadri M...Rich LJ	2019
38	Possible Relationship Between MYBL1 Alterations and Specific Primary Sites in Adenoid Cystic Carcinoma: A Clinicopathological and Molecular Study of 36 Cases. ( 30962747 )	Endo Y...Hirooka Y	2019
39	Cathepsin B defines leader cells during the collective invasion of salivary adenoid cystic carcinoma. ( 30968153 )	Wu JS...Tang YL	2019
40	The endocytic pathways of carbon dots in human adenoid cystic carcinoma cells. ( 30997713 )	Wei Y...Zhu B	2019
41	Treatment of adenoid cystic carcinoma of the mobile tongue with anterolateral thigh flap reconstruction: A case report. ( 31008961 )	Tang X...Zhang Y	2019
42	CCL2/CCR2 Axis Promotes the Progression of Salivary Adenoid Cystic Carcinoma via Recruiting and Reprogramming the Tumor-Associated Macrophages. ( 31024838 )	Yang Z...Yang X	2019
43	Tracheobronchial adenoid cystic carcinoma: 50-year experience at the National Cancer Center, China. ( 31026435 )	Wang Y...He J	2019
44	Detecting MYB and MYBL1 fusion genes in tracheobronchial adenoid cystic carcinoma by targeted RNA-sequencing. ( 31028361 )	Pei J...Wei S	2019
45	Definitive 125I Brachytherapy of Locally Advanced Adenoid Cystic Carcinoma Involving the Skull Base With Satisfying Efficacy and Safety. ( 31028735 )	Xu N...Zhang JG	2019
46	A Rare Case of Adenoid Cystic Carcinoma Isolated in the Mastoid. ( 31058605 )	Zhang J...Xiaoyun C	2019
47	Evaluation of Proliferative Marker Ki-67 in Adenoid Cystic Carcinoma: A Retrospective Study. ( 31058637 )	Bussari S...Kulkarni D	2019
48	Low recurrence of lung adenoid cystic carcinoma with radiotherapy and resection. ( 31067606 )	Sharma VJ...Antippa P	2019
49	Robot-Assisted Surgery Avoids Mandibulotomy in a Case of Adenoid Cystic Carcinoma of Base of the Tongue. ( 31073368 )	Vidhyadharan S...Iyer S	2019
50	Expression of MIF, Beclin1, and LC3 in human salivary gland adenoid cystic carcinoma and its prognostic value. ( 31096436 )	Li C...Liu H	2019

Sources

Genes for Adenoid Cystic Carcinoma

Genes related to Adenoid Cystic Carcinoma (6 elite genes):

(show top 50) (show all 58)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	TP53	Tumor Protein P53	Protein Coding	446.94	Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications Pathways & Interactions Variants (show sections)
2	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	444.37	Pathogenic ⁶ DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications Pathways & Interactions Variants (show sections)
3	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	430.97	Pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Pathways & Interactions Variants (show sections)
4	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	407.9	Pathogenic ⁶ GeneCards inferred via : Variants (show sections)
5	IDH1	Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic	Protein Coding	407.83	Pathogenic/Likely pathogenic ⁶ GeneCards inferred via : Variants (show sections)
6	JAK3	Janus Kinase 3	Protein Coding	407.48	Pathogenic ⁶ GeneCards inferred via : Variants (show sections)
7	NFIB	Nuclear Factor I B	Protein Coding	42.35	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications Pathways & Interactions (show sections)
8	NOTCH1	Notch Receptor 1	Protein Coding	42.04	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Pathways & Interactions Variants (show sections)
9	CYLD	CYLD Lysine 63 Deubiquitinase	Protein Coding	41.27	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	18008375 18234730 12023583 (more) 19462465 18718192 10835629 20227366
10	PTEN	Phosphatase And Tensin Homolog	Protein Coding	41.05	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Pathways & Interactions (show sections)
11	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	38.72	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications Pathways & Interactions (show sections)	7915830 17761983 1672262 (more) 19574086 12220353 19309723 8669836 1665502 7915079 14681328 15863127 16258515
12	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	38.01	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	14681323 19617878 15846389 (more) 16630292 16810311 16757202 16807072 20219417 15659505 10530560 12738950 16140564 14991904 15006985 18983466 16258515 16767900 18214402 16135502 20514080 16054424 16082245 10799746 17932891 19574086
13	KRT7	Keratin 7	Protein Coding	34.62	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	15899777 15982212 8835176 (more) 18564284 8835171 9129700
14	MYB	MYB Proto-Oncogene, Transcription Factor	Protein Coding	33.02	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Pathways & Interactions (show sections)
15	SERPINA3	Serpin Family A Member 3	Protein Coding	32.9	DISEASES inferred ¹⁵ ¹⁵ ¹⁵ ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	1665225 2175537 1281022
16	CCND1	Cyclin D1	Protein Coding	32.73	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	14714130 15943036 17129455 (more) 19659475 16865250 15195525 16078452 14747065 18605443 18481005 10928172
17	KRT14	Keratin 14	Protein Coding	32.52	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	7576573 15371944 9129700 (more) 15138813
18	CDH1	Cadherin 1	Protein Coding	32.11	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	17927866 15943036 10583557 (more) 15846389 9894453 17375572 12452045 15044918 16959701
19	STAT3	Signal Transducer And Activator Of Transcription 3	Protein Coding	32.08	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications Variants (show sections)
20	FBXW7	F-Box And WD Repeat Domain Containing 7	Protein Coding	30.66	DISEASES inferred ¹⁵ GeneCards inferred via : Pathways & Interactions Variants (show sections)
21	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	30.64	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Pathways & Interactions (show sections)
22	MUC1	Mucin 1, Cell Surface Associated	Protein Coding	30.25	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	11831973 12539531 1849991 (more) 15888109 7693778
23	MYBL1	MYB Proto-Oncogene Like 1	Protein Coding	29.03	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications Pathways & Interactions (show sections)
24	SMARCA2	SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 2	Protein Coding	20.07	DISEASES inferred ¹⁵ GeneCards inferred via : Pathways & Interactions Variants (show sections)
25	KRT20	Keratin 20	Protein Coding	19.75	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	10937047 15899777 11395563 (more) 15982212
26	ARID5B	AT-Rich Interaction Domain 5B	Protein Coding	19.74	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Pathways & Interactions (show sections)
27	VIM	Vimentin	Protein Coding	18.56	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	2175537 1692711 8835176 (more) 1646511 1711187 15735856 16807072 16785793 8015803 1283826 10981871 8393682
28	KRT19	Keratin 19	Protein Coding	17.86	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	8835171 15138813
29	SERPINB5	Serpin Family B Member 5	Protein Coding	17.74	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	18084258 17936671 11795829 (more) 18214402 16094606
30	CHEK2	Checkpoint Kinase 2	Protein Coding	17.6	GeneCards inferred via : Disorders Pathways & Interactions (show sections)
31	FGFR4	Fibroblast Growth Factor Receptor 4	Protein Coding	17.6	GeneCards inferred via : Disorders Pathways & Interactions (show sections)
32	BCOR	BCL6 Corepressor	Protein Coding	17.53	GeneCards inferred via : Pathways & Interactions Variants (show sections)
33	CREBBP	CREB Binding Protein	Protein Coding	17.35	GeneCards inferred via : Pathways & Interactions Variants (show sections)
34	RUNX3	RUNX Family Transcription Factor 3	Protein Coding	16.94	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
35	KRT5	Keratin 5	Protein Coding	16.85	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
36	ATM	ATM Serine/Threonine Kinase	Protein Coding	16.7	GeneCards inferred via : Publications Pathways & Interactions (show sections)
37	SOX4	SRY-Box 4	Protein Coding	16.3	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	16636670
38	SKA1	Spindle And Kinetochore Associated Complex Subunit 1	Protein Coding	16.22	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
39	ACTC1	Actin Alpha Cardiac Muscle 1	Protein Coding	16.15	Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	18084258 16810311 8835171 (more) 15899777
40	SOX10	SRY-Box 10	Protein Coding	16.04	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
41	RASSF1	Ras Association Domain Family Member 1	Protein Coding	16	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	15959912
42	EN1	Engrailed Homeobox 1	Protein Coding	15.94	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
43	PGR	Progesterone Receptor	Protein Coding	15.86	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
44	SBSN	Suprabasin	Protein Coding	15.82	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
45	CTNNB1	Catenin Beta 1	Protein Coding	15.17	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
46	NID1	Nidogen 1	Protein Coding	15.16	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	1315206
47	INSRR	Insulin Receptor Related Receptor	Protein Coding	15.06	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Pathways & Interactions (show sections)
48	TP63	Tumor Protein P63	Protein Coding	14.99	Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	15846389 16810311 18084258 (more) 19877114 15153875 12533521 18284937
49	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	14.99	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
50	S100A1	S100 Calcium Binding Protein A1	Protein Coding	14.94	Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	7693778 1646511

Sources

Variations for Adenoid Cystic Carcinoma

ClinVar genetic disease variations for Adenoid Cystic Carcinoma:

⁶ (show top 50) (show all 118)

#	Gene	Variation	Type	Significance	SNP ID	Assembly	Location
1	TP53	NM_000546.5(TP53): c.451C> A (p.Pro151Thr)	single nucleotide variant	Likely pathogenic	rs28934874	GRCh37	Chromosome 17, 7578479: 7578479
2	TP53	NM_000546.5(TP53): c.451C> A (p.Pro151Thr)	single nucleotide variant	Likely pathogenic	rs28934874	GRCh38	Chromosome 17, 7675161: 7675161
3	TP53	NM_000546.5(TP53): c.451C> T (p.Pro151Ser)	single nucleotide variant	Pathogenic/Likely pathogenic	rs28934874	GRCh37	Chromosome 17, 7578479: 7578479
4	TP53	NM_000546.5(TP53): c.451C> T (p.Pro151Ser)	single nucleotide variant	Pathogenic/Likely pathogenic	rs28934874	GRCh38	Chromosome 17, 7675161: 7675161
5	KRAS	NM_033360.3(KRAS): c.34G> C (p.Gly12Arg)	single nucleotide variant	Pathogenic	rs121913530	GRCh37	Chromosome 12, 25398285: 25398285
6	KRAS	NM_033360.3(KRAS): c.34G> C (p.Gly12Arg)	single nucleotide variant	Pathogenic	rs121913530	GRCh38	Chromosome 12, 25245351: 25245351
7	HRAS	NM_176795.4(HRAS): c.34G> A (p.Gly12Ser)	single nucleotide variant	Pathogenic	rs104894229	GRCh37	Chromosome 11, 534289: 534289
8	HRAS	NM_176795.4(HRAS): c.34G> A (p.Gly12Ser)	single nucleotide variant	Pathogenic	rs104894229	GRCh38	Chromosome 11, 534289: 534289
9	HRAS	NM_005343.2(HRAS): c.35G> C (p.Gly12Ala)	single nucleotide variant	Pathogenic	rs104894230	GRCh37	Chromosome 11, 534288: 534288
10	HRAS	NM_005343.2(HRAS): c.35G> C (p.Gly12Ala)	single nucleotide variant	Pathogenic	rs104894230	GRCh38	Chromosome 11, 534288: 534288
11	HRAS	NM_005343.2(HRAS): c.34G> T (p.Gly12Cys)	single nucleotide variant	Pathogenic	rs104894229	GRCh37	Chromosome 11, 534289: 534289
12	HRAS	NM_005343.2(HRAS): c.34G> T (p.Gly12Cys)	single nucleotide variant	Pathogenic	rs104894229	GRCh38	Chromosome 11, 534289: 534289
13	PIK3CA	NM_006218.3(PIK3CA): c.1258T> C (p.Cys420Arg)	single nucleotide variant	Pathogenic	rs121913272	GRCh37	Chromosome 3, 178927980: 178927980
14	PIK3CA	NM_006218.3(PIK3CA): c.1258T> C (p.Cys420Arg)	single nucleotide variant	Pathogenic	rs121913272	GRCh38	Chromosome 3, 179210192: 179210192
15	CREBBP	NM_004380.2(CREBBP): c.4336C> T (p.Arg1446Cys)	single nucleotide variant	Conflicting interpretations of pathogenicity	rs398124146	GRCh37	Chromosome 16, 3788618: 3788618
16	CREBBP	NM_004380.2(CREBBP): c.4336C> T (p.Arg1446Cys)	single nucleotide variant	Conflicting interpretations of pathogenicity	rs398124146	GRCh38	Chromosome 16, 3738617: 3738617
17	TP53	NM_000546.5(TP53): c.638G> A (p.Arg213Gln)	single nucleotide variant	Pathogenic	rs587778720	GRCh37	Chromosome 17, 7578211: 7578211
18	TP53	NM_000546.5(TP53): c.638G> A (p.Arg213Gln)	single nucleotide variant	Pathogenic	rs587778720	GRCh38	Chromosome 17, 7674893: 7674893
19	IDH1	NM_001282386.1(IDH1): c.395G> A (p.Arg132His)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913500	GRCh38	Chromosome 2, 208248388: 208248388
20	IDH1	NM_001282386.1(IDH1): c.395G> A (p.Arg132His)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913500	GRCh37	Chromosome 2, 209113112: 209113112
21	PIK3CA	NM_006218.3(PIK3CA): c.3129G> A (p.Met1043Ile)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913283	GRCh38	Chromosome 3, 179234286: 179234286
22	PIK3CA	NM_006218.3(PIK3CA): c.3129G> A (p.Met1043Ile)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913283	GRCh37	Chromosome 3, 178952074: 178952074
23	TP53	NM_000546.5(TP53): c.638G> C (p.Arg213Pro)	single nucleotide variant	Pathogenic/Likely pathogenic	rs587778720	GRCh37	Chromosome 17, 7578211: 7578211
24	TP53	NM_000546.5(TP53): c.638G> C (p.Arg213Pro)	single nucleotide variant	Pathogenic/Likely pathogenic	rs587778720	GRCh38	Chromosome 17, 7674893: 7674893
25	JAK3	NM_000215.3(JAK3): c.1765G> A (p.Gly589Ser)	single nucleotide variant	Pathogenic	rs886039394	GRCh37	Chromosome 19, 17947959: 17947959
26	JAK3	NM_000215.3(JAK3): c.1765G> A (p.Gly589Ser)	single nucleotide variant	Pathogenic	rs886039394	GRCh38	Chromosome 19, 17837150: 17837150
27	IDH1	NM_005896.3(IDH1): c.395G> T (p.Arg132Leu)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913500	GRCh37	Chromosome 2, 209113112: 209113112
28	IDH1	NM_005896.3(IDH1): c.395G> T (p.Arg132Leu)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913500	GRCh38	Chromosome 2, 208248388: 208248388
29	IDH1	NM_001282387.1(IDH1): c.394C> T (p.Arg132Cys)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913499	GRCh37	Chromosome 2, 209113113: 209113113
30	IDH1	NM_001282387.1(IDH1): c.394C> T (p.Arg132Cys)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913499	GRCh38	Chromosome 2, 208248389: 208248389
31	IDH1	NM_001282387.1(IDH1): c.394C> G (p.Arg132Gly)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913499	GRCh37	Chromosome 2, 209113113: 209113113
32	IDH1	NM_001282387.1(IDH1): c.394C> G (p.Arg132Gly)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913499	GRCh38	Chromosome 2, 208248389: 208248389
33	IDH1	NM_001282387.1(IDH1): c.394C> A (p.Arg132Ser)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913499	GRCh37	Chromosome 2, 209113113: 209113113
34	IDH1	NM_001282387.1(IDH1): c.394C> A (p.Arg132Ser)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913499	GRCh38	Chromosome 2, 208248389: 208248389
35	PIK3CA	NM_006218.3(PIK3CA): c.1035T> A (p.Asn345Lys)	single nucleotide variant	Likely pathogenic	rs121913284	GRCh37	Chromosome 3, 178921553: 178921553
36	PIK3CA	NM_006218.3(PIK3CA): c.1035T> A (p.Asn345Lys)	single nucleotide variant	Likely pathogenic	rs121913284	GRCh38	Chromosome 3, 179203765: 179203765
37	CREBBP	NM_004380.2(CREBBP): c.4337G> T (p.Arg1446Leu)	single nucleotide variant	Likely pathogenic	rs1057519884	GRCh37	Chromosome 16, 3788617: 3788617
38	CREBBP	NM_004380.2(CREBBP): c.4337G> T (p.Arg1446Leu)	single nucleotide variant	Likely pathogenic	rs1057519884	GRCh38	Chromosome 16, 3738616: 3738616
39	CREBBP	NM_004380.2(CREBBP): c.4337G> A (p.Arg1446His)	single nucleotide variant	Likely pathogenic	rs1057519884	GRCh37	Chromosome 16, 3788617: 3788617
40	CREBBP	NM_004380.2(CREBBP): c.4337G> A (p.Arg1446His)	single nucleotide variant	Likely pathogenic	rs1057519884	GRCh38	Chromosome 16, 3738616: 3738616
41	CREBBP	NM_004380.2(CREBBP): c.4336C> G (p.Arg1446Gly)	single nucleotide variant	Likely pathogenic	rs398124146	GRCh37	Chromosome 16, 3788618: 3788618
42	CREBBP	NM_004380.2(CREBBP): c.4336C> G (p.Arg1446Gly)	single nucleotide variant	Likely pathogenic	rs398124146	GRCh38	Chromosome 16, 3738617: 3738617
43	FBXW7	NM_001013415.2(FBXW7): c.1039C> T (p.Arg347Cys)	single nucleotide variant	Likely pathogenic	rs867384286	GRCh37	Chromosome 4, 153249385: 153249385
44	FBXW7	NM_001013415.2(FBXW7): c.1039C> T (p.Arg347Cys)	single nucleotide variant	Likely pathogenic	rs867384286	GRCh38	Chromosome 4, 152328233: 152328233
45	FBXW7	NM_001013415.2(FBXW7): c.1040G> A (p.Arg347His)	single nucleotide variant	Likely pathogenic	rs1057519895	GRCh37	Chromosome 4, 153249384: 153249384
46	FBXW7	NM_001013415.2(FBXW7): c.1040G> A (p.Arg347His)	single nucleotide variant	Likely pathogenic	rs1057519895	GRCh38	Chromosome 4, 152328232: 152328232
47	FBXW7	NM_001013415.2(FBXW7): c.1040G> C (p.Arg347Pro)	single nucleotide variant	Likely pathogenic	rs1057519895	GRCh37	Chromosome 4, 153249384: 153249384
48	FBXW7	NM_001013415.2(FBXW7): c.1040G> C (p.Arg347Pro)	single nucleotide variant	Likely pathogenic	rs1057519895	GRCh38	Chromosome 4, 152328232: 152328232
49	FBXW7	NM_001013415.2(FBXW7): c.1040G> T (p.Arg347Leu)	single nucleotide variant	Likely pathogenic	rs1057519895	GRCh37	Chromosome 4, 153249384: 153249384
50	FBXW7	NM_001013415.2(FBXW7): c.1040G> T (p.Arg347Leu)	single nucleotide variant	Likely pathogenic	rs1057519895	GRCh38	Chromosome 4, 152328232: 152328232

Cosmic variations for Adenoid Cystic Carcinoma:

⁹ (show top 50) (show all 15334)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location
1	COSM7410942	ZSWIM8	lung,NS,carcinoma,adenocarcinoma	c.2505G>A	p.G835G	10:73799190-73799190
2	COSM7411331	ZSWIM5	lung,NS,carcinoma,adenocarcinoma	c.2363C>A	p.P788H	1:45034398-45034398
3	COSM6926570	ZRSR2	lung,NS,carcinoma,adenocarcinoma	c.937+1G>T	p.?	23:15820317-15820317
4	COSM7411164	ZPBP	lung,NS,carcinoma,adenocarcinoma	c.966C>G	p.I322M	7:49937618-49937618
5	COSM7411425	ZPBP	lung,NS,carcinoma,adenocarcinoma	c.706G>T	p.V236F	7:50031092-50031092
6	COSM2768407	ZNF800	lung,NS,carcinoma,adenocarcinoma	c.1606C>T	p.R536*	7:127373730-127373730
7	COSM7411930	ZNF687	lung,NS,carcinoma,adenocarcinoma	c.2361C>G	p.H787Q	1:151289161-151289161
8	COSM7411692	ZNF608	lung,NS,carcinoma,adenocarcinoma	c.2023G>A	p.V675I	5:124648361-124648361
9	COSM7412390	ZNF536	lung,NS,carcinoma,adenocarcinoma	c.2770A>T	p.S924C	19:30548389-30548389
10	COSM1388126	ZNF521	lung,NS,carcinoma,adenocarcinoma	c.2365G>A	p.G789S	18:25225553-25225553
11	COSM1658882	ZNF507	salivary gland,NS,carcinoma,adenoid cystic carcinoma	c.34C>A	p.P12T	19:32352864-32352864
12	COSM7411528	ZNF423	lung,NS,carcinoma,adenocarcinoma	c.1122C>T	p.S374S	16:49638030-49638030
13	COSM7411524	ZNF423	lung,NS,carcinoma,adenocarcinoma	c.1436C>T	p.A479V	16:49637716-49637716
14	COSM7411526	ZNF423	lung,NS,carcinoma,adenocarcinoma	c.1157C>T	p.S386F	16:49637995-49637995
15	COSM7411530	ZNF423	lung,NS,carcinoma,adenocarcinoma	c.634C>A	p.H212N	16:49638518-49638518
16	COSM3712145	ZNF423	lung,NS,carcinoma,adenocarcinoma	c.609C>G	p.F203L	16:49638543-49638543
17	COSM7411916	ZNF326	lung,NS,carcinoma,adenocarcinoma	c.544G>A	p.E182K	1:90007679-90007679
18	COSM48853	ZMYND10	lung,NS,carcinoma,adenocarcinoma	c.622C>T	p.R208C	3:50342996-50342996
19	COSM48854	ZMYND10	lung,NS,carcinoma,adenocarcinoma	c.128A>G	p.N43S	3:50345197-50345197
20	COSM95558	ZMYM2	lung,NS,carcinoma,adenocarcinoma	c.95G>A	p.G32E	13:19993167-19993167
21	COSM7412277	ZIC5	lung,NS,carcinoma,adenocarcinoma	c.1583G>A	p.C528Y	13:99965786-99965786
22	COSM7411445	ZHX1	lung,NS,carcinoma,adenocarcinoma	c.1640C>T	p.T547M	8:123254307-123254307
23	COSM7411890	ZFX	lung,NS,carcinoma,adenocarcinoma	c.919C>T	p.Q307*	23:24207834-24207834
24	COSM6975161	ZFHX3	lung,NS,carcinoma,adenocarcinoma	c.5985C>G	p.I1995M	16:72796697-72796697
25	COSM6967535	ZFHX3	lung,NS,carcinoma,adenocarcinoma	c.3070G>T	p.A1024S	16:72950615-72950615
26	COSM6933870	ZFHX3	lung,NS,carcinoma,adenocarcinoma	c.3763C>T	p.P1255S	16:72811678-72811678
27	COSM6926444	ZFHX3	lung,NS,carcinoma,adenocarcinoma	c.10766C>G	p.S3589C	16:72787510-72787510
28	COSM6933260	ZFHX3	lung,NS,carcinoma,adenocarcinoma	c.256G>T	p.A86S	16:72959890-72959890
29	COSM6950021	ZFHX3	lung,NS,carcinoma,adenocarcinoma	c.2135G>T	p.R712L	16:72958011-72958011
30	COSM6972801	ZFHX3	lung,NS,carcinoma,adenocarcinoma	c.2680G>T	p.D894Y	16:72957466-72957466
31	COSM6982281	ZFHX3	lung,NS,carcinoma,adenocarcinoma	c.2701G>A	p.A901T	16:72957445-72957445
32	COSM6937412	ZFHX3	lung,NS,carcinoma,adenocarcinoma	c.1775A>C	p.D592A	16:72958371-72958371
33	COSM6969901	ZFHX3	lung,NS,carcinoma,adenocarcinoma	c.10802C>T	p.S3601L	16:72787474-72787474
34	COSM6931279	ZFHX3	lung,NS,carcinoma,adenocarcinoma	c.1530G>T	p.E510D	16:72958616-72958616
35	COSM6964729	ZFHX3	lung,NS,carcinoma,adenocarcinoma	c.5670G>C	p.Q1890H	16:72797012-72797012
36	COSM6935718	ZFHX3	lung,NS,carcinoma,adenocarcinoma	c.10628C>A	p.A3543D	16:72787648-72787648
37	COSM6929247	ZFHX3	lung,NS,carcinoma,adenocarcinoma	c.8677G>C	p.G2893R	16:72794005-72794005
38	COSM6945078	ZFHX3	lung,NS,carcinoma,adenocarcinoma	c.2755G>T	p.G919C	16:72950930-72950930
39	COSM6935881	ZFHX3	lung,NS,carcinoma,adenocarcinoma	c.1352G>T	p.C451F	16:72958794-72958794
40	COSM6940635	ZFHX3	lung,NS,carcinoma,adenocarcinoma	c.6289T>G	p.F2097V	16:72796393-72796393
41	COSM6969446	ZFHX3	lung,NS,carcinoma,adenocarcinoma	c.628G>T	p.G210C	16:72959518-72959518
42	COSM6926443	ZFHX3	lung,NS,carcinoma,adenocarcinoma	c.10885C>G	p.P3629A	16:72787391-72787391
43	COSM6968693	ZFHX3	lung,NS,carcinoma,adenocarcinoma	c.2767G>T	p.V923L	16:72950918-72950918
44	COSM6962405	ZFHX3	lung,NS,carcinoma,adenocarcinoma	c.10961C>T	p.S3654L	16:72787315-72787315
45	COSM6970007	ZFHX3	lung,NS,carcinoma,adenocarcinoma	c.3340C>G	p.R1114G	16:72889839-72889839
46	COSM6977567	ZFHX3	lung,NS,carcinoma,adenocarcinoma	c.4834G>C	p.E1612Q	16:72797848-72797848
47	COSM5796563	ZFHX3	lung,NS,carcinoma,adenocarcinoma	c.445C>T	p.Q149*	16:72959701-72959701
48	COSM6966467	ZFHX3	lung,NS,carcinoma,adenocarcinoma	c.5788T>C	p.S1930P	16:72796894-72796894
49	COSM6970295	ZFHX3	lung,NS,carcinoma,adenocarcinoma	c.1910G>A	p.G637E	16:72958236-72958236
50	COSM6968715	ZFHX3	lung,NS,carcinoma,adenocarcinoma	c.8982C>G	p.F2994L	16:72793700-72793700

Copy number variations for Adenoid Cystic Carcinoma from CNVD:

⁷ (show top 50) (show all 209)

#	CNVD ID	Chromosom	Start	End	Type	Gene Symbol	CNVD Disease
1	13805	1	1	61300000	Deletion		Adenoid cystic carcinoma
2	31809	1	31200000	32688000	Loss	BAI2	Adenoid cystic carcinoma
3	31810	1	31200000	32688000	Loss	EIF3S2	Adenoid cystic carcinoma
4	31811	1	31200000	32688000	Loss	FABP3	Adenoid cystic carcinoma
5	31812	1	31200000	32688000	Loss	HDAC1	Adenoid cystic carcinoma
6	31813	1	31200000	32688000	Loss	IQCC	Adenoid cystic carcinoma
7	31814	1	31200000	32688000	Loss	KHDRBS1	Adenoid cystic carcinoma
8	31815	1	31200000	32688000	Loss	LCK	Adenoid cystic carcinoma
9	31816	1	31200000	32688000	Loss	MARCKSL1	Adenoid cystic carcinoma
10	31817	1	31200000	32688000	Loss	PTP4A2	Adenoid cystic carcinoma
11	31818	1	31200000	32688000	Loss	PUM1	Adenoid cystic carcinoma
12	31819	1	31200000	32688000	Loss	RBBP4	Adenoid cystic carcinoma
13	31820	1	31200000	32688000	Loss	SERINC2	Adenoid cystic carcinoma
14	31821	1	31200000	32688000	Loss	TXLNA	Adenoid cystic carcinoma
15	33928	1	50618000	52179000	Loss	CDKN2C	Adenoid cystic carcinoma
16	33929	1	50618000	52179000	Loss	EPS15	Adenoid cystic carcinoma
17	33930	1	50618000	52179000	Loss	FAF1	Adenoid cystic carcinoma
18	33931	1	50618000	52179000	Loss	NRD1	Adenoid cystic carcinoma
19	33932	1	50618000	52179000	Loss	RAB3B	Adenoid cystic carcinoma
20	33933	1	50618000	52179000	Loss	RNF11	Adenoid cystic carcinoma
21	50143	11	114500000	121200000	Deletion		Adenoid cystic carcinoma
22	50146	11	114500000	121200000	Gain		Salivary gland adenoid cystic carcinoma
23	58545	11	68400000	70400000	Deletion		Adenoid cystic carcinoma
24	58546	11	68400000	70400000	Gain		Salivary gland adenoid cystic carcinoma
25	61970	12	103800000	109000000	LOH		Adenoid cystic carcinoma
26	64283	12	125900000	133851895	LOH		Adenoid cystic carcinoma
27	67068	12	35800000	133851895	Loss		Adenoid cystic carcinoma
28	67236	12	38200000	58100000	Deletion		Adenoid cystic carcinoma
29	67639	12	43743000	50676000	Loss	ACVR1B	Adenoid cystic carcinoma
30	67640	12	43743000	50676000	Loss	ACVRL1	Adenoid cystic carcinoma
31	67641	12	43743000	50676000	Loss	ADCY6	Adenoid cystic carcinoma
32	67642	12	43743000	50676000	Loss	AMIGO2	Adenoid cystic carcinoma
33	67643	12	43743000	50676000	Loss	ANP32D	Adenoid cystic carcinoma
34	67644	12	43743000	50676000	Loss	ARF3	Adenoid cystic carcinoma
35	67645	12	43743000	50676000	Loss	ATF1	Adenoid cystic carcinoma
36	67646	12	43743000	50676000	Loss	CCNT1	Adenoid cystic carcinoma
37	67647	12	43743000	50676000	Loss	COL2A1	Adenoid cystic carcinoma
38	67648	12	43743000	50676000	Loss	DDX23	Adenoid cystic carcinoma
39	67649	12	43743000	50676000	Loss	FAIM2	Adenoid cystic carcinoma
40	67650	12	43743000	50676000	Loss	HDAC7A	Adenoid cystic carcinoma
41	67651	12	43743000	50676000	Loss	LALBA	Adenoid cystic carcinoma
42	67652	12	43743000	50676000	Loss	LETMD1	Adenoid cystic carcinoma
43	67653	12	43743000	50676000	Loss	LIMA1	Adenoid cystic carcinoma
44	67654	12	43743000	50676000	Loss	MLL2	Adenoid cystic carcinoma
45	67655	12	43743000	50676000	Loss	PFKM	Adenoid cystic carcinoma
46	67656	12	43743000	50676000	Loss	PLEKHA9	Adenoid cystic carcinoma
47	67657	12	43743000	50676000	Loss	PRKAG1	Adenoid cystic carcinoma
48	67658	12	43743000	50676000	Loss	RACGAP1	Adenoid cystic carcinoma
49	67659	12	43743000	50676000	Loss	RAPGEF3	Adenoid cystic carcinoma
50	67660	12	43743000	50676000	Loss	RHEBL1	Adenoid cystic carcinoma

Sources

Expression for Adenoid Cystic Carcinoma

Search GEO for disease gene expression data for Adenoid Cystic Carcinoma.

Sources

Pathways for Adenoid Cystic Carcinoma

Pathways related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 114)

#	Super pathways	Score	Top Affiliating Genes
1	Signaling by GPCR ⁶⁷ Show member pathways GPCR downstream signaling ⁶⁷ Signal Transduction ⁶⁷	14.27	CCND1 CDH1 CYLD ERBB2 FBXW7 HRAS
2	Innate Immune System ⁶⁷ Show member pathways Immune System ⁶⁷ Neutrophil degranulation ⁶⁷	14.1	CCND1 CDH1 CYLD ERBB2 FBXW7 HRAS
3	ERK Signaling ⁶⁵ Show member pathways ILK Signaling ⁶⁵ MAPK Signaling ⁶⁵ Molecular Mechanisms of Cancer ⁶⁵ Rho Family GTPases ⁶⁵	13.96	CCND1 CDH1 ERBB2 HRAS JAK3 KIT
4	HIV Life Cycle ⁶⁷ Show member pathways 2-LTR circle formation ⁶⁷ APOBEC3G mediated resistance to HIV-1 infection ⁶⁷ Assembly Of The HIV Virion ⁶⁷ Binding and entry of HIV virion ⁶⁷ Disease ⁶⁷ Diseases of signal transduction ⁶⁷ Early Phase of HIV Life Cycle ⁶⁷ HIV Infection ⁶⁷ Host Interactions of HIV factors ⁶⁷ Infectious disease ⁶⁷ Integration of provirus ⁶⁷ Late Phase of HIV Life Cycle ⁶⁷	13.82	CDH1 ERBB2 FBXW7 HRAS IDH1 KIT
5	GPCR Pathway ⁶⁵ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶⁵ Estrogen Pathway ⁶⁵ NFAT in Immune Response ⁶⁵ P2Y Receptor Signaling ⁶⁵ Pancreatic Adenocarcinoma ⁶⁵ Paxillin Interactions ⁶⁵ Ras Pathway ⁶⁵	13.81	CCND1 ERBB2 HRAS JAK3 KIT KRAS
6	TGF-Beta Pathway ⁶⁵ Show member pathways JAK-STAT Pathway ⁶⁵ JNK Pathway ⁶⁵ MAPK Family Pathway ⁶⁵ Regulation of eIF4 and p70S6K ⁶⁵ SOCS Pathway ⁶⁵	13.64	CDH1 ERBB2 HRAS JAK3 KIT KRAS
7	Developmental Biology ⁶⁷ Show member pathways Axon guidance ⁶⁷	13.61	ERBB2 HRAS JAK3 KIT KRAS KRT14
8	Class I MHC mediated antigen processing and presentation ⁶⁷ Show member pathways Adaptive Immune System ⁶⁷ Antigen processing- Ubiquitination and Proteasome degradation ⁶⁷	13.56	CDH1 ERBB2 FBXW7 HRAS KIT KRAS
9	Akt Signaling ⁶⁵ Show member pathways p38 Signaling ⁶⁵ Tec Kinases Signaling ⁶⁵	13.52	CCND1 ERBB2 HRAS JAK3 KIT KRAS
10	Cytokine Signaling in Immune system ⁶⁷ Show member pathways Signaling by Interleukins ⁶⁷	13.48	CCND1 ERBB2 HRAS JAK3 KIT KRAS
11	Response to elevated platelet cytosolic Ca2+ ⁶⁷ Show member pathways Disinhibition of SNARE formation ⁶⁷ Hemostasis ⁶⁷ Platelet activation, signaling and aggregation ⁶⁷ Platelet degranulation ⁶⁷	13.4	HRAS JAK3 KRAS MYB PIK3CA SERPINA3
12	PAK Pathway ⁶⁵ Show member pathways Antioxidant Action of Vitamin-C ⁶⁵ Epithelial Adherens Junctions ⁶⁵	13.38	CDH1 ERBB2 HRAS KIT KRAS NOTCH1
13	IL-2 Pathway ⁶⁵ Show member pathways ErbB Family Pathway ⁶⁵ ErbB2-ErbB3 Heterodimers ⁶⁵ ErbB4 Pathway ⁶⁵ Growth Hormone Signaling ⁶⁵ HMGB1 Pathway ⁶⁵ IL-4 Pathway ⁶⁵ LPS Stimulated MAPK Signaling ⁶⁵ PACAP Signaling ⁶⁵ PI3K Signaling in B-Lymphocyte ⁶⁵ Prolactin Signaling ⁶⁵ Thrombopoietin Pathway ⁶⁵ TREM1 Pathway ⁶⁵ UVC-Induced MAPK Signaling ⁶⁵	13.32	CCND1 ERBB2 HRAS JAK3 KRAS PTEN
14	Human cytomegalovirus infection ³⁸ Show member pathways Human immunodeficiency virus 1 infection ³⁸ Kaposi sarcoma-associated herpesvirus infection ³⁸	13.07	CCND1 HRAS KRAS PIK3CA PTEN STAT3
15	Focal Adhesion ¹ ³⁸ Show member pathways HGF Pathway ⁶⁵ Integrin-mediated Cell Adhesion ¹	13.02	CCND1 ERBB2 HRAS KRAS PIK3CA PTEN
16	Regulation of lipid metabolism Insulin signaling-generic cascades ²³ Show member pathways acetyl-CoA biosynthesis from citrate ¹ Butyrate-induced histone acetylation ¹ Cell adhesion PLAU signaling ²³ Class IB PI3K non-lipid kinase events ¹ Development CNTF receptor signaling ²³ Development Growth hormone signaling via PI3K/AKT and MAPK cascades ²³ ErbB2/ErbB3 signaling events ¹ Glucose Homeostasis ¹ Insulin signaling pathway ³⁸ IRS activation ⁶⁷ Signal attenuation ⁶⁷ Transcription Receptor-mediated HIF regulation ²³ Translation Regulation of EIF2 activity ²³ Translation Regulation of EIF4F activity ²³ Translation Insulin regulation of translation ²³	13	ERBB2 HRAS KRAS PIK3CA PTEN STAT3
17	CCR5 Pathway in Macrophages ⁶⁵ Show member pathways Androgen Signaling ⁶⁵ Chemokine Signaling ⁶⁵ Chemokine signaling pathway ³⁸	12.99	CCND1 HRAS JAK3 KRAS PIK3CA STAT3
18	NFAT and Cardiac Hypertrophy ⁶⁵ Show member pathways IGF1R Signaling ⁶⁵ Signaling Involved in Cardiac Hypertrophy ⁶⁵	12.99	ERBB2 HRAS JAK3 KRAS PIK3CA PTEN
19	PI3K-Akt signaling pathway ³⁸ Show member pathways Human papillomavirus infection ³⁸	12.98	CCND1 ERBB2 HRAS JAK3 KIT KRAS
20	Endometrial cancer ³⁸ Show member pathways Acute myeloid leukemia ³⁸ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁷ Chronic myeloid leukemia ³⁸ Colorectal cancer ³⁸ Pancreatic cancer ³⁸ Prostate cancer ³⁸ Signal transduction PTEN pathway ²³ Thyroid cancer ³⁸	12.9	CCND1 CDH1 ERBB2 HRAS KIT KRAS
21	Common Cytokine Receptor Gamma-Chain Family Signaling Pathways ⁶⁶ Show member pathways Adipokines and Insulin Signaling Pathways ⁶⁶ Development Thrombopoietin-regulated cell processes ²³ IL-15 Signaling Pathways ⁶⁶ IL-2 Signaling Pathways ⁶⁶ IL-21 Signaling Pathways ⁶⁶ IL-4 Signaling Pathways ⁶⁶ IL-7 Signaling Pathways ⁶⁶ IL-9 Pathway ⁶⁵ IL-9 Signaling Pathways ⁶⁶ Immune response IL-9 signaling pathway ²³	12.89	CCND1 HRAS JAK3 KRAS PIK3CA PTEN
22	MAPK signaling pathway ¹ ³⁸	12.85	ERBB2 HRAS KIT KRAS TP53
23	Downstream signaling events of B Cell Receptor (BCR) ⁶⁷ Show member pathways Activation of RAS in B cells ⁶⁷ Signaling by the B Cell Receptor (BCR) ⁶⁷	12.83	ERBB2 HRAS KIT KRAS PIK3CA PTEN
24	Ras signaling pathway ³⁸ Show member pathways Rap1 signaling pathway ³⁸	12.81	CDH1 HRAS KIT KRAS PIK3CA
25	Development HGF signaling pathway ²³ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²³ Apoptosis and survival NGF signaling pathway ²³ Apoptosis and survival Role of CDK5 in neuronal death and survival ²³ Development Neurotrophin family signaling ²³ MET activates PTPN11 ⁶⁷ MET activates STAT3 ⁶⁷ Neurotrophin signaling pathway ³⁸ Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ¹ Signaling of Hepatocyte Growth Factor Receptor ¹	12.8	CDH1 ERBB2 HRAS KRAS PIK3CA PTEN
26	4-1BB Pathway ⁶⁵ Show member pathways CD27 Pathway ⁶⁵ CD40 Signaling ⁶⁵ CMV and MAPK Pathways ⁶⁵ NF-KappaB Activation by EBV ⁶⁵ NF-kappaB Activation by Viruses ⁶⁵ PKR Pathway ⁶⁵ SUMO Pathway ⁶⁵ TNFR2 Pathway ⁶⁵	12.77	HRAS JAK3 KRAS STAT3 TP53
27	Development Endothelin-1/EDNRA signaling ²³ Show member pathways Cytoskeleton remodeling FAK signaling ²³ Development Endothelin-1/EDNRA transactivation of EGFR ²³ GnRH signaling pathway ³⁸ Inflammatory mediator regulation of TRP channels ³⁸	12.75	CCND1 HRAS KRAS PIK3CA PTEN
28	Immune response IL-23 signaling pathway ²³ Show member pathways Angiopoietin receptor Tie2-mediated signaling ¹ Angiopoietin-TIE2 Signaling ⁶⁵ Development Angiopoietin - Tie2 signaling ²³ Development PDGF signaling via STATs and NF-kB ²³ IL23-mediated signaling events ¹ Immune response IL-10 signaling pathway ²³ Rac1/Pak1/p38/MMP-2 pathway ¹	12.72	ERBB2 HRAS KRAS PIK3CA STAT3 TP53
29	ErbB signaling pathway ¹ ³⁸ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁶² EGFR tyrosine kinase inhibitor resistance ³⁸ Renal cell carcinoma ³⁸ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.7	CCND1 ERBB2 HRAS KRAS PIK3CA STAT3
30	Gastric cancer ³⁸ Show member pathways Breast cancer ³⁸ Hepatocellular carcinoma ³⁸	12.69	CCND1 CDH1 ERBB2 HRAS KIT KRAS
31	NF-kappaB Signaling ⁴	12.67	CYLD JAK3 KIT MYB STAT3
32	Pathways in cancer ³⁸	12.66	CCND1 CDH1 ERBB2 HRAS JAK3 KIT
33	mTOR signaling pathway (KEGG) ³⁸ Show member pathways mTOR Signaling Pathway ⁶⁶	12.63	ERBB2 HRAS KRAS PIK3CA PTEN TP53
34	Prolactin Signaling Pathway ¹ ³⁸ Show member pathways Development Prolactin receptor signaling ²³ Leptin signaling pathway ¹	12.61	CCND1 ERBB2 HRAS KRAS PIK3CA PTEN
35	Development EGFR signaling pathway ²³ Show member pathways Development ERBB-family signaling ²³ EGF Pathway ⁶⁵ EGFR Signaling Pathway ⁶⁸ ErbB receptor signaling network ¹	12.6	CCND1 CDH1 ERBB2 HRAS KRAS PIK3CA
36	Glioma ³⁸ Show member pathways Endocrine resistance ³⁸ Melanoma ³⁸ Non-small cell lung cancer ³⁸ Signaling Pathways in Glioblastoma ¹	12.59	CCND1 CDH1 ERBB2 HRAS JAK3 KRAS
37	Apoptosis Pathway ⁷³ Show member pathways Akt Pathway ⁷³ NF-kappaB Pathway ⁷³	12.56	ERBB2 HRAS KRAS PIK3CA TP53
38	MET promotes cell motility ⁶⁷ Show member pathways Alpha 6 Beta 4 signaling pathway ¹ Laminin interactions ⁶⁷ MET activates PTK2 signaling ⁶⁷ MET activates RAP1 and RAC1 ⁶⁷ MET activates RAS signaling ⁶⁷ MET interacts with TNS proteins ⁶⁷ MET Receptor Activation ⁶⁷ MET receptor recycling ⁶⁷ Non-integrin membrane-ECM interactions ⁶⁷ Signaling by MET ⁶⁷ Syndecan interactions ⁶⁷	12.54	HRAS KRAS PIK3CA STAT3
39	JAK-STAT signaling pathway (KEGG) ⁶⁶ Show member pathways Interleukin-19, 20, 22, 24 ⁶⁷ JAK-STAT signaling pathway ³⁸	12.53	CCND1 HRAS JAK3 KRAS PIK3CA STAT3
40	Development VEGF signaling via VEGFR2 - generic cascades ²³ Show member pathways Development VEGF signaling and activation ²³ VEGF - VEGF R2 Signaling Pathways ⁶⁶	12.52	HRAS JAK3 KRAS PIK3CA STAT3
41	AMP-activated Protein Kinase (AMPK) Signaling ¹ Show member pathways AMPK signaling pathway ³⁸ AMPK Signaling Pathway ⁶⁸	12.51	CCND1 HRAS PIK3CA TP53
42	G-protein signaling RAC1 in cellular process ²³ Show member pathways CDC42 signaling events ¹ Cytoskeleton remodeling CDC42 in cellular processes ²³ RAC1 signaling pathway ¹	12.51	CDH1 ERBB2 HRAS KIT KRAS PIK3CA
43	MicroRNAs in cancer ³⁸	12.5	CCND1 ERBB2 HRAS KRAS NOTCH1 PIK3CA
44	Development IGF-1 receptor signaling ²³ Show member pathways IL-4 Signaling Pathway ¹ Immune response IL-4 signaling pathway ²³ Signal transduction AKT signaling ²³	12.49	CCND1 HRAS JAK3 PIK3CA PTEN STAT3
45	Phospholipase D signaling pathway ³⁸ Show member pathways Choline metabolism in cancer ³⁸	12.48	HRAS KIT KRAS PIK3CA
46	B cell receptor signaling pathway (KEGG) ³⁸ Show member pathways B Cell Receptor Signaling Pathway ¹ BCR signaling pathway ¹	12.46	HRAS KRAS PIK3CA PTEN
47	Human T-cell leukemia virus 1 infection ³⁸	12.46	CCND1 HRAS JAK3 KRAS MYB PIK3CA
48	CNTF Signaling ⁶⁵ Show member pathways FLT3 Signaling ⁶⁵ IL-3 Pathway ⁶⁵ Nur77-Induced AICD in Macrophage ⁶⁵ OSM Pathway ⁶⁵	12.42	HRAS JAK3 KRAS STAT3
49	Development A3 receptor signaling ²³ Show member pathways Development A1 receptor signaling ²³ G-protein signaling G-Protein alpha-q signaling cascades ²³	12.41	CCND1 HRAS PIK3CA STAT3
50	B Cell Receptor Signaling Pathway (sino) ⁶⁸ Show member pathways T Cell Receptor Signaling Pathway ⁶⁸	12.41	HRAS KRAS PIK3CA PTEN

Sources

GO Terms for Adenoid Cystic Carcinoma

Cellular components related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cytosol	GO:0005829	9.8	CCND1 CYLD ERBB2 FBXW7 IDH1 JAK3
2	cytoplasm	GO:0005737	9.55	CCND1 CDH1 CYLD ERBB2 FBXW7 HRAS
3	cytoplasmic side of plasma membrane	GO:0009898	9.33	CDH1 KIT PTEN

Biological processes related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

(show all 27)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of cell migration	GO:0030335	9.92	HRAS KIT NOTCH1 STAT3
2	cell proliferation	GO:0008283	9.91	ERBB2 HRAS PTEN STAT3 TP53
3	negative regulation of cell proliferation	GO:0008285	9.91	HRAS NFIB NOTCH1 PTEN STAT3 TP53
4	positive regulation of protein phosphorylation	GO:0001934	9.83	CCND1 ERBB2 HRAS KRAS
5	MAPK cascade	GO:0000165	9.8	ERBB2 HRAS JAK3 KIT KRAS
6	positive regulation of cell proliferation	GO:0008284	9.8	CCND1 HRAS KIT KRAS NOTCH1 PTEN
7	response to organic cyclic compound	GO:0014070	9.78	CCND1 IDH1 PTEN STAT3
8	Ras protein signal transduction	GO:0007265	9.77	HRAS KRAS TP53
9	response to organic substance	GO:0010033	9.76	CCND1 CDH1 PTEN STAT3
10	positive regulation of epithelial cell proliferation	GO:0050679	9.72	ERBB2 HRAS NOTCH1
11	positive regulation of Notch signaling pathway	GO:0045747	9.67	KIT NOTCH1 STAT3
12	liver development	GO:0001889	9.67	CCND1 KRAS NOTCH1 PIK3CA
13	regulation of mitochondrial membrane permeability	GO:0046902	9.63	STAT3 TP53
14	response to leptin	GO:0044321	9.63	CCND1 STAT3
15	cellular response to leptin stimulus	GO:0044320	9.62	PTEN STAT3
16	positive regulation of MAP kinase activity	GO:0043406	9.62	ERBB2 HRAS KIT KRAS
17	somatic stem cell division	GO:0048103	9.61	KIT NOTCH1
18	interleukin-9-mediated signaling pathway	GO:0038113	9.6	JAK3 STAT3
19	astrocyte differentiation	GO:0048708	9.58	NOTCH1 STAT3
20	enzyme linked receptor protein signaling pathway	GO:0007167	9.58	ERBB2 JAK3
21	interleukin-21-mediated signaling pathway	GO:0038114	9.57	JAK3 STAT3
22	mitotic G1 DNA damage checkpoint	GO:0031571	9.56	CCND1 TP53
23	positive regulation of ERK1 and ERK2 cascade	GO:0070374	9.55	FBXW7 HRAS KIT NOTCH1 PTEN
24	response to isolation stress	GO:0035900	9.54	HRAS KRAS
25	cytokine-mediated signaling pathway	GO:0019221	9.5	CCND1 JAK3 KIT KRAS PIK3CA STAT3
26	positive regulation of gene expression	GO:0010628	9.23	ERBB2 HRAS KIT KRAS NOTCH1 PTEN
27	negative regulation of transcription by RNA polymerase II	GO:0000122	10.08	CCND1 MYB NFIB NOTCH1 STAT3 TP53

Molecular functions related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein binding	GO:0005515	9.91	CCND1 CDH1 CYLD ERBB2 FBXW7 HRAS
2	RNA polymerase II proximal promoter sequence-specific DNA binding	GO:0000978	9.8	MYB NFIB NOTCH1 STAT3 TP53
3	protein kinase binding	GO:0019901	9.77	CCND1 CYLD PTEN STAT3 TP53
4	identical protein binding	GO:0042802	9.7	CDH1 ERBB2 FBXW7 IDH1 PTEN STAT3
5	nucleotide binding	GO:0000166	9.65	ERBB2 HRAS JAK3 KIT KRAS
6	phosphatidylinositol-4,5-bisphosphate 3-kinase activity	GO:0046934	9.02	PIK3CA
7	protein phosphatase binding	GO:0019903	8.92	ERBB2 JAK3 STAT3 TP53

Sources

Sources for Adenoid Cystic Carcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia